Maria Zannes - bioAffinity

bioAffinity Technologies Reports Second Quarter 2025 Results

by Maria Zannes | Aug 14, 2025 | Press Releases

CyPath® Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung...

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

by Maria Zannes | Aug 13, 2025 | Press Releases

SAN ANTONIO, Texas (August 13, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase...

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

by Maria Zannes | Aug 13, 2025 | Press Releases

July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO, TX – August 13, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge...

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results

by Maria Zannes | Jul 29, 2025 | Press Releases

bioAffinity Technologies’ noninvasive sputum test catches rare cancer in time for curative surgery SAN ANTONIO, TX – July 29, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer...

Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

by Maria Zannes | Jul 23, 2025 | Press Releases

bioAffinity Technologies’ noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A SAN ANTONIO, TX – July 23, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate...